{"prompt": "['OSTPDL1', 'Page 71 of 60', '12. Kolb EA, Gorlick R, Reynolds CP, et al: Initial testing (stage 1) of', 'eribulin, a novel tubulin binding agent, by the pediatric preclinical testing', 'program. Pediatr Blood Cancer 60:1325-32, 2013', '13.', 'Bielack SS, Smeland S, Whelan JS, et al: Methotrexate, Doxorubicin,', 'and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP', 'Alone in Patients With Resectable High-Grade Osteosarcoma and Good', 'Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good', 'Response Randomized Controlled Trial. J Clin Oncol 33:2279-87, 2015', '14. Marina N, Smeland S, Bielack SS, et al: MAPIE vs. MAP in patients', 'with a poor resopnse to pre-operative chemotherapy for newly diagnosed', 'osteosarcoma: results from EURAMOS-1 Connective Tissue Oncology Society.', 'Berlin, Germany, 2014', '15. Chen X, Bahrami A, Pappo A, et al: Recurrent somatic structural', 'variations contribute to tumorigenesis in pediatric osteosarcoma. Cell Rep', '7:104-12, 2014', '16.', 'Perry JA, Kiezun A, Tonzi P, et al: Complementary genomic', 'approaches highlight the PI3K/mTOR pathway as a common vulnerability in', 'osteosarcoma. Proc Natl Acad Sci U S A 111:E5564-73, 2014', '17. Postow MA, Callahan MK, Wolchok JD: Immune Checkpoint', 'Blockade in Cancer Therapy. J Clin Oncol 33:1974-82, 2015', '18. Garon EB, Rizvi NA, Hui R, et al: Pembrolizumab for the treatment', 'of non-small-cell lung cancer. N Engl J Med 372:2018-28, 2015', '19. Le DT, Uram JN, Wang H, et al: PD-1 Blockade in Tumors with', 'Mismatch-Repair Deficiency. N Engl J Med 372:2509-20, 2015', '20. Gettinger SN, Horn L, Gandhi L, et al: Overall Survival and Long-', 'Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558,', 'ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung', 'Cancer. J Clin Oncol, 2015', '21. McDermott DF, Drake CG, Sznol M, et al: Survival, Durable', 'Response, and Long-Term Safety in Patients With Previously Treated Advanced', 'Renal Cell Carcinoma Receiving Nivolumab. J Clin Oncol, 2015', '22. Postow MA, Chesney J, Pavlick AC, et al: Nivolumab and ipilimumab', 'versus ipilimumab in untreated melanoma. N Engl J Med 372:2006-17, 2015', '23. Ansell SM, Lesokhin AM, Borrello I, et al: PD-1 blockade with', \"nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med\", '372:311-9, 2015', '24. Larkin J, Chiarion-Sileni V, Gonzalez R, et al: Combined Nivolumab', 'and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med, 2015', '25. Tumeh PC, Harview CL, Yearley JH, et al: PD-1 blockade induces', 'responses by inhibiting adaptive immune resistance. Nature 515:568-71, 2014', '26. Platten M, Offringa R: Cancer immunotherapy: exploiting', 'neoepitopes. Cell Res, 2015', '27. Snyder A, Wolchok JD, Chan TA: Genetic basis for clinical response', 'to CTLA-4 blockade. N Engl J Med 372:783, 2015', \"28. Lussier DM, O'Neill L, Nieves LM, et al: Enhanced T-cell immunity to\", 'osteosarcoma through antibody blockade of PD-1/PD-L1 interactions. J', 'Immunother 38:96-106, 2015', 'St. Jude', 'IRB NUMBER: Pro00006856', 'Revision 1.1, dated: 01-19-2018', 'IRB approved: DATE: 06/26/2019', 'Protocol document dated: 01-19-2018']['OSTPDL1', 'Page 72 of 60', '29. Lussier DM, Johnson JL, Hingorani P, et al: Combination', 'immunotherapy with alpha-CTLA-4 and alpha-PD-L1 antibody blockade', 'prevents immune escape and leads to complete control of metastatic', 'osteosarcoma. J Immunother Cancer 3:21, 2015', '30.', 'Shen JK, Cote GM, Choy E, et al: Programmed cell death ligand 1', 'expression in osteosarcoma. Cancer Immunol Res 2:690-8, 2014', '31. Tawbi HA-H, Burgess MA, Crowley J, et al: Safety and efficacy of', 'PD-1 blockade using pembrolizumab in patients with advanced soft tissue (STS)', 'and bone sarcomas (BS): Results of SARC028--A multicenter phase II study.', 'ASCO Meeting Abstracts 34:11006, 2016', '32. Keir ME, Butte MJ, Freeman GJ, et al: PD- - 1 and its ligands in', 'tolerance and immunity. Annu Rev Immunol 26:677-704, 2008', '33. Okazaki T, Honjo T: PD-1 and PD-1 ligands: from discovery to', 'clinical application. Int Immunol 19:813-24, 2007', '34. Rizvi NA, Hellmann MD, Snyder A, et al: Cancer immunology.', 'Mutational landscape determines sensitivity to PD-1 blockade in non-small cell', 'lung cancer. Science 348:124-8, 2015', '35. van Rooij N, van Buuren MM, Philips D, et al: Tumor exome analysis', 'reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive', 'melanoma. J Clin Oncol 31:e439-42, 2013', '36.', 'Restifo NP, Dudley ME, Rosenberg SA: Adoptive immunotherapy for', 'cancer: harnessing the T cell response. Nat Rev Immunol 12:269-81, 2012', '37. Aquino d: Challenges and future perspectives of T cell', 'immunotherapy in cancer. Immunology letters 166:117-133 2015', '38. Wherry EJ: T cell exhaustion. Nat Immunol 12:492-9, 2011', '39. Wherry EJ, Ha SJ, Kaech SM, et al: Molecular signature of CD8+ T', 'cell exhaustion during chronic viral infection. Immunity 27:670-84, 2007', '40. Sharma P, Allison JP: The future of immune checkpoint therapy.', 'Science 348:56-61, 2015', '41. Blackburn SD, Shin H, Haining WN, et al: Coregulation of CD8+ T', 'cell exhaustion by multiple inhibitory receptors during chronic viral infection.', 'Nat Immunol 10:29-37, 2009', '42. Peretz Y, He Z, Shi Y, et al: CD160 and PD-1 co-expression on HIV-', 'specific CD8 T cells defines a subset with advanced dysfunction. PLoS Pathog', '8:e1002840, 2012', '43. Gros A, Robbins PF, Yao X, et al: PD-1 identifies the patient-', 'specific CD8(+) tumor-reactive repertoire infiltrating human tumors. J Clin', 'Invest 124:2246-59, 2014', '44. Duraiswamy J, Ibegbu CC, Masopust D, et al: Phenotype, function,', 'and gene expression profiles of programmed death-1(hi) CD8 T cells in healthy', 'human adults. J Immunol 186:4200-12, 2011', '45. Twyman-Saint Victor C, Rech AJ, Maity A, et al: Radiation and dual', 'checkpoint blockade activate non-redundant immune mechanisms in cancer.', 'Nature 520:373-7, 2015', '46. La Gruta NL, Thomas PG: Interrogating the relationship between', 'naive and immune antiviral T cell repertoires. Curr Opin Virol 3:447-51, 2013', 'St. Jude', 'IRB NUMBER: Pro00006856', 'Revision 1.1, dated: 01-19-2018', 'IRB approved: 01-26-301 APPROVAL DATE: 06/26/2019', 'Protocol document dated: 01-19-2018']\n\n###\n\n", "completion": "END"}